RxDoctor Payments DataLook up a doctor →

Marc Yelle, MD

Pain Medicine · Raleigh, NCNPI 1871889501

Payments from drug & device makers

$18,928in general payments, 2019–2025

Across 432 payments — averaging $43.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Medtronic$2K
  • MML US, Inc.$2K
  • Biotronik NRO, Inc.$1K
  • Boston Scientific$864
  • Vertos Medical, Inc.$768
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$3,46818%
  • Food & beverage$15,30181%
  • Education$1601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,928 in reported general payments places this provider in the 85th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$157,505
Medicare patients
248
Services billed
7,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levorphanol Tartrate17$77,040
NucyntaTapentadol Hcl22$23,014
Xtampza ErOxycodone Myristate19$11,138
Aimovig AutoinjectorErenumab-Aooe12$8,688
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen156$3,199
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen121$2,021
Oxycodone Hcl112$1,761
Gabapentin111$1,539
Pregabalin52$949
Morphine Sulfate ErMorphine Sulfate29$667
Diclofenac Sodium29$622
Tizanidine Hcl59$606
Tramadol Hcl ErTramadol Hcl12$557
Celecoxib18$390
Tramadol Hcl59$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Virtus Pharmaceuticals LLCLevorphanol Tartrate$180$77,04017 claims
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er$217$34,15241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →